Cancer Genome Study Using Samples From Patients With Stage I or Stage II Non-Small Cell Lung Cancer Treated on Clinical Trial ACOSOG-Z0030

Study Overview
=================
Brief Summary
-----------------
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research study is looking at the cancer genome using tumor samples from patients with stage I or stage II non-small cell lung cancer treated on clinical trial ACOSOG-Z0030.

Detailed Description
-----------------
OBJECTIVES: To investigate the clinical relevance of conducting comprehensive molecular analyses on clinically annotated high-quality tumor biospecimens from patients with stage I or II, N0 or N1 (less than hilar) non-small cell lung cancer. OUTLINE: This is a multicenter study. Biological specimens are collected from participating clinical sites and analyzed by transcription profiling of RNA and microRNA; detection of DNA copy number changes and chromosomal rearrangements; epigenetic modifications analyses; and sequencing of genomic segments, genes, and regulatory regions to assess sequence variation. Clinical information associated with each specimen donor is also collected.

Official Title
-----------------
The Cancer Genome Atlas (TCGA) Utilizing Z0030 NSCLC Patient Samples

Conditions
-----------------
Lung Cancer

Intervention / Treatment
-----------------
* Genetic: DNA analysis
* Genetic: RNA analysis
* Genetic: microarray analysis
* Genetic: mutation analysis
* Genetic: polymorphism analysis


Participation Criteria
=================
Eligibility Criteria
-----------------
DISEASE CHARACTERISTICS: Diagnosis of non-small cell carcinoma Primary, untreated disease Stage I or II (T1 or T2, N0 or non-hilar N1, M0) disease Any of the following histologies allowed: Squamous cell carcinoma Adenocarcinoma (< 10%) Large cell carcinoma (high-grade) Available tumor tissue samples collected on clinical trial ACOSOG-Z0030 and meeting the following criteria: Snap-frozen and stored at a temperature of -80°C or lower Specimens may come from any site within the lung or one that is involved by direct regional extension of tumor from the originating site in the lung No regional lymph node or distant metastases No recurrent or persistent disease after prior neoadjuvant or adjuvant treatment for lung cancer Must have matching frozen samples of normal tissue and blood

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group 1<br>This research study is looking at the cancer genome using tumor samples from patients with stage I or stage II non-small cell lung cancer treated on clinical trial ACOSOG-Z0030. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. | Genetic: DNA analysis<br> <br> Genetic: RNA analysis<br> <br> Genetic: microarray analysis<br> <br> Genetic: mutation analysis<br> <br> Genetic: polymorphism analysis<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical relevance of conducting comprehensive molecular analyses on clinically annotated high-quality tumor biospecimens |  | Up to 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
adenocarcinoma of the lung, large cell lung cancer, squamous cell lung cancer, stage I non-small cell lung cancer, stage II non-small cell lung cancer